Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.98
TKPYY's Cash to Debt is ranked lower than
63% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. TKPYY: 0.98 )
Ranked among companies with meaningful Cash to Debt only.
TKPYY' s 10-Year Cash to Debt Range
Min: 0.82  Med: 62.91 Max: N/A
Current: 0.98
Equity to Asset 0.50
TKPYY's Equity to Asset is ranked lower than
63% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. TKPYY: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
TKPYY' s 10-Year Equity to Asset Range
Min: 0.5  Med: 0.73 Max: 0.8
Current: 0.5
0.5
0.8
F-Score: 4
Z-Score: 2.30
M-Score: -2.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -7.27
TKPYY's Operating margin (%) is ranked higher than
55% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. TKPYY: -7.27 )
Ranked among companies with meaningful Operating margin (%) only.
TKPYY' s 10-Year Operating margin (%) Range
Min: -7.27  Med: 26.92 Max: 35.13
Current: -7.27
-7.27
35.13
Net-margin (%) -8.05
TKPYY's Net-margin (%) is ranked lower than
59% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.85 vs. TKPYY: -8.05 )
Ranked among companies with meaningful Net-margin (%) only.
TKPYY' s 10-Year Net-margin (%) Range
Min: -8.05  Med: 18.97 Max: 26.26
Current: -8.05
-8.05
26.26
ROE (%) -5.98
TKPYY's ROE (%) is ranked lower than
63% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.87 vs. TKPYY: -5.98 )
Ranked among companies with meaningful ROE (%) only.
TKPYY' s 10-Year ROE (%) Range
Min: -6.21  Med: 14.41 Max: 24.22
Current: -5.98
-6.21
24.22
ROA (%) -3.17
TKPYY's ROA (%) is ranked lower than
61% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. TKPYY: -3.17 )
Ranked among companies with meaningful ROA (%) only.
TKPYY' s 10-Year ROA (%) Range
Min: -3.23  Med: 10.98 Max: 16.8
Current: -3.17
-3.23
16.8
ROC (Joel Greenblatt) (%) -16.95
TKPYY's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.80 vs. TKPYY: -16.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TKPYY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -19.36  Med: 135.67 Max: 210.61
Current: -16.95
-19.36
210.61
Revenue Growth (3Y)(%) 5.80
TKPYY's Revenue Growth (3Y)(%) is ranked higher than
51% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. TKPYY: 5.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TKPYY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0.2  Med: 4.90 Max: 11.6
Current: 5.8
0.2
11.6
EBITDA Growth (3Y)(%) -28.30
TKPYY's EBITDA Growth (3Y)(%) is ranked lower than
67% of the 476 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. TKPYY: -28.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TKPYY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -28.3  Med: 1.30 Max: 24.8
Current: -28.3
-28.3
24.8
» TKPYY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with TKPYY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.21
TKPYY's P/B is ranked higher than
74% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. TKPYY: 2.21 )
Ranked among companies with meaningful P/B only.
TKPYY' s 10-Year P/B Range
Min: 1.23  Med: 1.52 Max: 2.44
Current: 2.21
1.23
2.44
P/S 2.63
TKPYY's P/S is ranked higher than
59% of the 661 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. TKPYY: 2.63 )
Ranked among companies with meaningful P/S only.
TKPYY' s 10-Year P/S Range
Min: 1.67  Med: 2.18 Max: 12.29
Current: 2.63
1.67
12.29
POCF 392.42
TKPYY's POCF is ranked lower than
98% of the 399 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.21 vs. TKPYY: 392.42 )
Ranked among companies with meaningful POCF only.
TKPYY' s 10-Year POCF Range
Min: 7.19  Med: 17.05 Max: 434.86
Current: 392.42
7.19
434.86
EV-to-EBIT -42.93
TKPYY's EV-to-EBIT is ranked higher than
50% of the 480 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.91 vs. TKPYY: -42.93 )
Ranked among companies with meaningful EV-to-EBIT only.
TKPYY' s 10-Year EV-to-EBIT Range
Min: -41  Med: 10.90 Max: 67.2
Current: -42.93
-41
67.2
Shiller P/E 34.41
TKPYY's Shiller P/E is ranked higher than
67% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 40.23 vs. TKPYY: 34.41 )
Ranked among companies with meaningful Shiller P/E only.
TKPYY' s 10-Year Shiller P/E Range
Min: 10.17  Med: 16.88 Max: 34.17
Current: 34.41
10.17
34.17
Current Ratio 1.49
TKPYY's Current Ratio is ranked lower than
56% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. TKPYY: 1.49 )
Ranked among companies with meaningful Current Ratio only.
TKPYY' s 10-Year Current Ratio Range
Min: 1.49  Med: 3.63 Max: 5.39
Current: 1.49
1.49
5.39
Quick Ratio 1.24
TKPYY's Quick Ratio is ranked higher than
51% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. TKPYY: 1.24 )
Ranked among companies with meaningful Quick Ratio only.
TKPYY' s 10-Year Quick Ratio Range
Min: 1.24  Med: 3.35 Max: 5.13
Current: 1.24
1.24
5.13
Days Inventory 188.36
TKPYY's Days Inventory is ranked lower than
80% of the 616 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.37 vs. TKPYY: 188.36 )
Ranked among companies with meaningful Days Inventory only.
TKPYY' s 10-Year Days Inventory Range
Min: 47.73  Med: 139.93 Max: 180.99
Current: 188.36
47.73
180.99

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.05
TKPYY's Dividend Yield is ranked higher than
88% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. TKPYY: 3.05 )
Ranked among companies with meaningful Dividend Yield only.
TKPYY' s 10-Year Dividend Yield Range
Min: 1.55  Med: 4.52 Max: 5.83
Current: 3.05
1.55
5.83
Dividend Payout 2.58
TKPYY's Dividend Payout is ranked lower than
98% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.31 vs. TKPYY: 2.58 )
Ranked among companies with meaningful Dividend Payout only.
TKPYY' s 10-Year Dividend Payout Range
Min: 0.21  Med: 0.33 Max: 1.33
Current: 2.58
0.21
1.33
Yield on cost (5-Year) 1.56
TKPYY's Yield on cost (5-Year) is ranked higher than
82% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.34 vs. TKPYY: 1.56 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TKPYY' s 10-Year Yield on cost (5-Year) Range
Min: 1.55  Med: 4.52 Max: 5.83
Current: 1.56
1.55
5.83
Share Buyback Rate 0.10
TKPYY's Share Buyback Rate is ranked lower than
198% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -2.40 vs. TKPYY: 0.10 )
Ranked among companies with meaningful Share Buyback Rate only.
TKPYY' s 10-Year Share Buyback Rate Range
Min: 3.2  Med: 0.10 Max: -0.1
Current: 0.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 8.04
TKPYY's Price/Tangible Book is ranked lower than
74% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.30 vs. TKPYY: 8.04 )
Ranked among companies with meaningful Price/Tangible Book only.
TKPYY' s 10-Year Price/Tangible Book Range
Min: 1.94  Med: 2.53 Max: 8.55
Current: 8.04
1.94
8.55
Price/Projected FCF 0.92
TKPYY's Price/Projected FCF is ranked higher than
83% of the 315 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. TKPYY: 0.92 )
Ranked among companies with meaningful Price/Projected FCF only.
TKPYY' s 10-Year Price/Projected FCF Range
Min: 0.48  Med: 0.77 Max: 1.1
Current: 0.92
0.48
1.1
Price/Median PS Value 1.08
TKPYY's Price/Median PS Value is ranked higher than
59% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. TKPYY: 1.08 )
Ranked among companies with meaningful Price/Median PS Value only.
TKPYY' s 10-Year Price/Median PS Value Range
Min: 0.87  Med: 1.04 Max: 1.18
Current: 1.08
0.87
1.18
Price/Graham Number 5.20
TKPYY's Price/Graham Number is ranked lower than
77% of the 367 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.75 vs. TKPYY: 5.20 )
Ranked among companies with meaningful Price/Graham Number only.
TKPYY' s 10-Year Price/Graham Number Range
Min: 1.03  Med: 1.37 Max: 3.41
Current: 5.2
1.03
3.41
Earnings Yield (Greenblatt) (%) -2.24
TKPYY's Earnings Yield (Greenblatt) (%) is ranked higher than
65% of the 698 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. TKPYY: -2.24 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TKPYY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -2.27  Med: 8.60 Max: 23.1
Current: -2.24
-2.27
23.1
Forward Rate of Return (Yacktman) (%) -13.36
TKPYY's Forward Rate of Return (Yacktman) (%) is ranked lower than
85% of the 307 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. TKPYY: -13.36 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TKPYY' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -20.9  Med: -9.70 Max: 17.2
Current: -13.36
-20.9
17.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:4502.Japan, TKD.Germany, 4502.Japan, 4502.Japan,
Takeda Pharmaceutical Co Ltd was founded on June 12, 1781 and was incorporated on January 29, 1925. The Company is primarily engaged in the any manufacture and sale of pharmaceuticals, food supplements, and chemical products such as polyurethane. The Company also produces food, agrochemicals, and environment-related products such as pollution detectors. It is also engaged in the research, development, and promotion of its products through its related companies in the US, Europe, and Asia.
» More Articles for TKPYY

Headlines

Articles On GuruFocus.com
5 Popular Asian Stocks Held By the Gurus Apr 16 2015 
Don't Quit on Teva Just Yet Feb 20 2014 
Soros´ Bet on Teva’s Transition (A Transition for Better or for Worse?) Dec 18 2013 
T. Rowe Price Japan Fund Top 5 New Buys Oct 17 2013 

More From Other Websites
Questions for Takeda as CFO jumps ship Jun 24 2015
Nobel Laureate Allies With Takeda in Hunt for Blockbuster Drugs Jun 15 2015
Orexigen, Takeda file suit against Actavis to stop generic diet pill Jun 05 2015
Takeda Reports Top Line Results in Line With Guidance, With Underlying Growth of +2.8% EPS Affected... May 15 2015
Orexigen shares fall in quarrel with Takeda over drug study May 13 2015
Takeda Pharmaceutical Company Limited -- Moody's: Takeda's rating not immediately impacted by ACTOS... May 01 2015
Vivus Goes on a Diet: Sales Reps are Cut, but Will FDA Help Save Money? Apr 02 2015
Infinity Pharmaceuticals Exercises Duvelisib Royalty Option - Analyst Blog Apr 01 2015
Leerink: Europe Deal Coming For Orexigen Therapeutics Mar 30 2015
Orexigen's Obesity Drug Mysimba Gains European Approval - Analyst Blog Mar 27 2015
Novo Nordisk's Saxenda: New Data from Phase IIIa Study - Analyst Blog Mar 09 2015
Takeda Disagrees With Orexigen Over Data Disclosure Mar 05 2015
Orexigen Soars as Interim Data on Contrave Comes to Light - Analyst Blog Mar 04 2015
Orexigen (OREX) Misses Q4 Earnings, Contrave Impresses - Analyst Blog Feb 26 2015
Takeda Regroups Singapore Operations in New, Expanded Office Feb 24 2015
Seattle Genetics (SGEN) Filed Supplemental BLA for Adcetris - Analyst Blog Feb 19 2015
Seattle Genetics Posts Narrower-than-Expected Loss in Q4 - Analyst Blog Feb 11 2015
Orexigen Gives Positive Updates on its Weight Loss Drug - Analyst Blog Feb 10 2015
AMAG's Q4 Loss Narrows Y/Y, Reiterates 2015 Outlook - Analyst Blog Feb 10 2015
AstraZeneca's Regulatory Filing for Lesinurad Accepted - Analyst Blog Jan 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK